The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib

Karthick Vishwanathan, Paul A. Dickinson, Karen So, Karen Thomas, Yuh-Min Chen, Javier Carpeno, Anne-Marie C. Dingemans, Hye Ryun Kim, Joo-Hang Kim, Matthew G. Krebs, James Chih-Hsin Yang, Bui Bui, Doris Weilert, R. Donald Harvey

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1156-1169
Number of pages14
JournalBritish Journal of Clinical Pharmacology
Volume84
Issue number6
DOIs
Publication statusPublished - 1 Jun 2018

Keywords

  • clinical pharmacology
  • drug metabolism
  • drug analysis
  • lung cancer
  • drug information
  • oncology
  • pharmacokinetics
  • biomarkers
  • drug interactions
  • CELL LUNG-CANCER
  • SYSTEMIC ANTIMYCOTICS KETOCONAZOLE
  • GROWTH-FACTOR RECEPTOR
  • DRUG-DRUG INTERACTION
  • PHASE-III
  • OPEN-LABEL
  • ACQUIRED-RESISTANCE
  • 1ST-LINE TREATMENT
  • T790M MUTATION
  • EGFR MUTATIONS

Cite this

Vishwanathan, K., Dickinson, P. A., So, K., Thomas, K., Chen, Y-M., Carpeno, J., Dingemans, A-M. C., Kim, H. R., Kim, J-H., Krebs, M. G., Yang, J. C-H., Bui, B., Weilert, D., & Harvey, R. D. (2018). The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. British Journal of Clinical Pharmacology, 84(6), 1156-1169. https://doi.org/10.1111/bcp.13534